How Medtech Companies Can Enhance Procedural Workflow and Capture Intra-Operative Data

Prana Surgical CEO Joanna Nathan is developing a surgical platform for precision lung cancer treatment and has raised $12 million to date — from venture capital as well non-dilutive sources. She shares her framework for evaluating which medtech ideas merit pursuit, revealing three critical signals every founder should look for: clinical urgency that requires no convincing, favorable asymmetry between value and technical risk, and optimal market timing. Joanna also demonstrates how systematic grant applications and strategic resource allocation can extend runway while building investor credibility, and addresses the unique psychological challenges of building life-critical devices.

Firefly Neuroscience CEO Greg Lipschitz brings capital markets expertise to scaling an AI platform that objectively measures brain function through EEG analysis. With a proprietary database spanning twelve cognitive disorders, the company serves both clinical practitioners and pharmaceutical partners. Greg shares insights on strategic fundraising approaches, platform prioritization decisions, and building commercial momentum in healthcare through direct sales and customer feedback loops.

Anumana, an AI-driven health technology company focused on cardiovascular care, is taking a pragmatic approach to scaling AI in medicine. By developing software-as-a-medical-device solutions that fit into existing clinical workflows, Anumana emphasizes usability and rigorous validation over hype. CEO Maulik Nanavaty shares why building a strong risk-benefit case and designing around real-world clinician needs are key to adoption. With data from over 20 million patients and a focus on transparency, Anumana is reshaping how AI reaches the point of care.